Su1398 SEVEN-DAY VONOPRAZAN AND LOW-DOSE AMOXICILLIN DUAL THERAPY AS FIRST-LINE HELICOBACTER PYLORI TREATMENT: A MULTICENTER RANDOMIZED TRIAL IN JAPAN

Kasai, Toyotaka; Suzuki, Shuichi; Kusano, Chika; Ikehara, Hisatomo; Ichijima, Ryoji; Esaki, Mitsuru; Shibuya, Hitoshi; Horii, Toshiki; Kawabe, Koichi; Eto, Hiroyuki; Ohyauchi, Motoki; Ito, Hirotaka; Kawamura, Masashi; Ogata, Yohei; Ohtaka, Masahiko; Yoda, Yoshioki; Nakahara, Moriyasu; Gotoda, Takuji

doi:10.1016/s0016-5085(20)32149-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, when vonoprazan-based triple therapy is given to patients harboring clarithromycinresistant strains, it is like giving a dual therapy and the superiority of vonoprazan triple therapy over PPI triple therapy [145] is likely due to a superior pharmacologic synergy between the P-CAB and the amoxicillin component compared to a standard DR-PPI-amoxicillin combination. Available studies [153][154][155][156][157], summarized in Table 5, and a meta-analysis of them [158] confirm this. A pooled eradication rate of 85.6% (95% CI: 74.8 to 94.0) was found, albeit with evidence of significant heterogeneity (I 2 =64.8%).…”

Section: Efficacy Of Vonoprazan-based Eradication Regimensmentioning

confidence: 79%

Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

Scarpignato

Hunt

2021

Curr Treat Options Gastro

View full text Add to dashboard Cite

Purpose of the review The introduction of H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) into clinical practice has been a real breakthrough in the treatment of acid-related diseases. PPIs are now the standard of care for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), Helicobacter pylori infection, NSAID-associated gastroduodenal lesions, and upper gastrointestinal bleeding (UGIB). However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. Recent findings To address these needs, new long-acting compounds (such as tenatoprazole and AGN 201904-Z) and new PPI formulations, including instant release omeprazole (IR-omeprazole) and dexlansoprazole modified release (MR), have been developed. However, a major advance has been the development of the potassium-competitive acid blockers (P-CABs), which block the K+,H+-ATPase potassium channel, are food independent, are reversible, have a rapid onset of action, and maintain a prolonged and consistent elevation of intragastric pH. Vonoprazan and tegoprazan are the two marketed P-CABs while two other compounds (namely fexuprazan and X842) are under active development. Available for almost 6 years now, a considerable experience has been accumulated with vonoprazan, the efficacy and safety of which are detailed in this paper, together with the preliminary results of the other members of this new pharmacologic class. Summary Based on the available evidence, erosive reflux disease, H. pylori infection, and secondary prevention of NSAID gastropathy can be considered established indications for vonoprazan and are being explored for tegoprazan and fexuprazan. In the treatment of severe (LA C & D) reflux esophagitis and H. pylori eradication, vonoprazan proved to be superior to PPIs. Other uses of P-CABs are being evaluated, but clinical data are not yet sufficient to allow a definitive answer on its efficacy and possible superiority over the current standard of care (i.e., PPIs). The most notable indication of upper GI (non-variceal) bleeding, where vonoprazan would prove superior to PPIs, has not yet been explored. The safety of P-CABs in the short-term overlaps that of PPIs, but data from long-term treatment are needed.

show abstract